0.59
전일 마감가:
$0.598
열려 있는:
$0.5925
하루 거래량:
11,916
Relative Volume:
0.24
시가총액:
$18.94M
수익:
$8.59M
순이익/손실:
$-17.07M
주가수익비율:
-0.9672
EPS:
-0.61
순현금흐름:
$-21.90M
1주 성능:
-3.29%
1개월 성능:
-24.63%
6개월 성능:
-59.86%
1년 성능:
-49.14%
Durect Corp Stock (DRRX) Company Profile
명칭
Durect Corp
전화
(408) 777-1417
주소
10240 BUBB ROAD, CUPERTINO, CA
DRRX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
DRRX
Durect Corp
|
0.59 | 18.94M | 8.59M | -17.07M | -21.90M | -0.61 |
![]()
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.78B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2020-10-30 | 개시 | Chardan Capital Markets | Buy |
2020-10-12 | 개시 | ROTH Capital | Buy |
2020-07-31 | 개시 | Oppenheimer | Outperform |
2020-01-31 | 개시 | B. Riley FBR | Buy |
2019-11-18 | 재개 | Cantor Fitzgerald | Overweight |
2019-09-06 | 개시 | Cantor Fitzgerald | Overweight |
2018-03-06 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2017-10-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2017-10-20 | 재확인 | Laidlaw | Buy |
2017-10-20 | 다운그레이드 | Stifel | Buy → Hold |
2017-07-12 | 업그레이드 | Stifel | Hold → Buy |
2017-02-28 | 재개 | H.C. Wainwright | Buy |
2016-04-25 | 개시 | Rodman & Renshaw | Buy |
2015-05-01 | 재확인 | Cantor Fitzgerald | Buy |
2015-05-01 | 재확인 | Stifel | Buy |
2013-03-25 | 개시 | Stifel | Buy |
2012-11-01 | 다운그레이드 | C.K. Cooper | Buy → Hold |
2012-08-17 | 개시 | C.K. Cooper | Buy |
2009-06-23 | 개시 | Caris & Company | Buy |
2009-03-26 | 개시 | Wedbush Morgan | Hold |
모두보기
Durect Corp 주식(DRRX)의 최신 뉴스
DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com - Defense World
Durect Corp stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Durect Corp stock hits 52-week low at $0.69 amid market challenges - Investing.com
Form 8-KCurrent report - ADVFN
DURECT Co. (NASDAQ:DRRX) Sees Large Decline in Short Interest - Defense World
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT (DRRX) to Release Quarterly Earnings on Wednesday - Defense World
DURECT Q4 Earnings Preview: Key Financial Results and Strategic Updates Coming March 26 - Stock Titan
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Exclusive Healthcare Conference Alert: DURECT CEO Reveals Latest Developments - Stock Titan
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Durect Corp (DRRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):